CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 144 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2016. The put-call ratio across all filers is 0.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $61,000 | -17.6% | 26,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $74,000 | -12.9% | 26,000 | -12.8% | 0.00% | 0.0% |
| Q3 2017 | $85,000 | +3.7% | 29,800 | -9.7% | 0.00% | 0.0% |
| Q2 2017 | $82,000 | -32.8% | 33,000 | -2.7% | 0.00% | -50.0% |
| Q1 2017 | $122,000 | -10.3% | 33,900 | -11.5% | 0.00% | 0.0% |
| Q4 2016 | $136,000 | -9.3% | 38,300 | +3.0% | 0.00% | 0.0% |
| Q3 2016 | $150,000 | – | 37,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,006 | $3,457,000 | 100.00% |
| Meditor Group Ltd | 6,312,700 | $3,179,000 | 0.62% |
| TSP Capital Management Group, LLC | 1,328,207 | $669,000 | 0.34% |
| GREAT POINT PARTNERS LLC | 804,483 | $405,000 | 0.06% |
| Telemetry Investments, L.L.C. | 252,300 | $127,000 | 0.05% |
| Centiva Capital, LP | 187,749 | $95,000 | 0.02% |
| Benchmark Capital Advisors | 54,400 | $27,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 639,800 | $322,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 79,400 | $40,000 | 0.01% |
| LMR Partners LLP | 408,846 | $206,000 | 0.01% |